DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM Apr 17, 2018
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research Apr 16, 2018
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma Dec 26, 2017
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting Nov 21, 2017
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer Oct 31, 2017
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer Oct 3, 2017
